Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. - Wikidata - awgldk - TriplyDB

Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis.

Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis.

http://www.wikidata.org/entity/Q33400720

about

New Antituberculosis Drugs: From Clinical Trial to Programmatic Use Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis Carbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic Review Management of multidrug-resistant TB: novel treatments and their expansion to low resource settings Emerging strategies for the treatment of pulmonary tuberculosis: promise and limitations?Extensively drug-resistant tuberculosis: epidemiology and management WHO group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review with cohort analysis and meta-analysis New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid Rising to the challenge: new therapies for tuberculosis Recent developments in the diagnosis and management of tuberculosis.Cost Resulting from Anti-Tuberculosis Drug Shortages in the United States: A Hypothetical Cohort Study Linezolid-Associated Optic Neuropathy in Drug-Resistant Tuberculosis Patients in Mumbai, India New anti-tuberculosis drugs and regimens: 2015 update Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.Insights into the pharmacokinetic properties of antitubercular drugs.Individualizing management of extensively drug-resistant tuberculosis: diagnostics, treatment, and biomarkers.Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis.Early Bactericidal Activity of AZD5847 in Patients with Pulmonary Tuberculosis.Linezolid Induced Twice Pure Red Cell Aplasia in a Patient with Central Nervous System Infection after Allogeneic Stem Cell Transplantation.Population pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients.Linezolid manifests a rapid and dramatic therapeutic effect for patients with life-threatening tuberculous meningitis.Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function High rate of hypothyroidism in multidrug-resistant tuberculosis patients co-infected with HIV in Mumbai, India Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis.Tuberculosis treatment and drug regimens.Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines.The multidrug-resistant tuberculosis threat: old problems and new solutions Linezolid in the Starter Combination for Multidrug-Resistant Tuberculosis: Time to Move on to Group Four?Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis Linezolid Trough Concentrations Correlate with Mitochondrial Toxicity-Related Adverse Events in the Treatment of Chronic Extensively Drug-Resistant Tuberculosis.Can intermittent dosing optimize prolonged linezolid treatment of difficult multidrug-resistant tuberculosis?TBNET - Collaborative research on tuberculosis in Europe.Assessment of linezolid efficacy, safety and tolerability in the treatment of tuberculosis: A retrospective case review Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: study protocol for a prospective, multicenter, randomized, open-label, phase II trial.Management of difficult multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: update 2012.Therapeutic drug monitoring in the treatment of tuberculosis: an update.Delamanid when other anti-tuberculosis-treatment regimens failed due to resistance or tolerability.Antibiotic-induced neurotoxicity.Delamanid (OPC-67683) for treatment of multi-drug-resistant tuberculosis.Bedaquiline for the treatment of drug-resistant tuberculosis.

P2860

Q26741138-5D2688AA-1A79-4262-94BF-B1D8E5F0B41E Q26743380-75000549-F123-4BB5-8E57-B03321B24E2F Q26764847-C0B61201-420A-4808-A7F4-864FF1261A2A Q26765394-11518372-C9CB-4767-A3C7-EE38644BF8D9 Q26771997-B566A829-AF25-42FC-9BC9-AFEF60AD4A0B Q26830094-AA47E40C-DAF4-45A9-930C-92E86770E591 Q26852253-6C29E72B-99A0-46BB-A114-4E3EAAEB0C1B Q27003210-2C594D6F-8D45-4CAF-987D-FFF5D7A9D61C Q27011672-9FC808AA-48BF-4176-AAEB-F17CD3AD3F34 Q28077124-8C014244-B97A-40C6-8CCC-C6704FCB4057 Q28547335-E6626EDB-1B1B-4A67-A3B2-7FA25E595502 Q28553960-F68F772D-465F-4A69-9B17-CEDC1545E281 Q28596775-1159FF38-9D16-41EA-8AFA-2448923E1268 Q30236048-D208F3DC-B9BB-4715-8072-CEC4947E59BD Q30251497-AC87E79D-998E-49B3-B941-242259899B1C Q30275673-074DB335-A38A-4C86-8840-26D179B6D433 Q30573127-B523C559-BF85-453F-8A4F-A585C6A12E3E Q33434791-8C430401-8DE7-4C77-827F-A9E0ECDAB9B2 Q33435423-94E99BEC-28A9-4A54-B914-D9654A2BC102 Q33439246-B1CF6CA9-998C-4C0C-B5D2-E6404130FDC3 Q34299173-7588F449-A39C-4629-BD2D-6E63D10651B6 Q34922189-B01B6789-82F4-4BC2-97E9-F269C1BD0DC3 Q35032535-331768AF-8F54-481B-9687-AD629B01F66C Q35568367-7A8FC4C8-F373-4580-8641-B646D11598AF Q35663866-41B0875D-15B3-440C-8D1C-3E0590DAEEC0 Q36094215-9F5D7476-1FF5-49D8-9808-C4D12E5DC54D Q36138237-67323BDD-533C-4C4C-94F1-31A19A14607D Q36402705-6DC6C5A3-1CAA-4B0D-94F9-8EA74456EE01 Q36439105-EACE6080-5CE1-48FC-8A83-EEB17D1154BD Q36540988-ECF7B842-20FA-47ED-9993-A527C4CCA210 Q36969745-8E00F5CF-2237-4CB5-9CEC-B93B340E7A74 Q37319949-3904F73D-29FC-40A9-81DD-65D430254B30 Q37366765-4BBA2789-9739-4D7D-AF60-BA9FA9AD8841 Q37640769-08C5B39D-D8C8-48B7-9D85-70C7565CFA2D Q38040155-04F8B802-89F8-400F-82F8-35FC1B615FD9 Q38213320-8C8AB085-583A-4E8E-9167-FA2CFB2C1AB7 Q38261230-AE07E224-3460-4285-B907-850013B21218 Q38263096-6C9D913B-072A-44E9-A27E-34B744BA11DB Q38341918-A2C3D637-5155-4B3E-BEF7-D73F4A47ED85 Q38386950-451653D3-D151-4756-950A-A1EFC2396C88

P2860

Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis.

http://www.wikidata.org/entity/Q33400720

description

2012 nî lūn-bûn

@nan

2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Efficacy, safety and tolerabil ...... atic review and meta-analysis.

@ast

Efficacy, safety and tolerabil ...... atic review and meta-analysis.

@en

type

label

Efficacy, safety and tolerabil ...... atic review and meta-analysis.

@ast

Efficacy, safety and tolerabil ...... atic review and meta-analysis.

@en

prefLabel

Efficacy, safety and tolerabil ...... atic review and meta-analysis.

@ast

Efficacy, safety and tolerabil ...... atic review and meta-analysis.

@en

P1433

Q33400720-C9F17D48-C6BA-4F2A-A98E-A63718EA42B4

P1476

Q33400720-22FAED0C-F729-49AD-AA4C-5A5A854DA247

P2093

Q33400720-412ADC91-FA58-4306-8651-ABCF52D0F98D

Q33400720-41B5050F-393A-42DD-AEA0-D5B9ADBEC569

Q33400720-473AE134-7B9D-4443-898D-E63B16441FA5

Q33400720-4FF8B0F6-1AAE-4274-ADB9-56B815C4CD16

Q33400720-5A745252-2F71-4B16-8F4A-BEA7828F59A4

Q33400720-603B6BFC-36A7-44EC-9435-9A1D9FFA785E

Q33400720-609101AD-8762-4938-9BE6-0EDE5DAE899F

Q33400720-9227073B-7B94-4C43-AD68-E55B944DB8EB

Q33400720-B9ABAD26-6FD9-43A7-8E03-2C3CA13743E2

Q33400720-C4CE394C-72BA-41CF-AA73-1622EDCCBADC

P304

Q33400720-ABE26F98-BD4D-457F-85A4-FD2493A05C3F

P31

Q33400720-309822B9-E8A5-4400-AEC6-63067296E37E

Q33400720-4e522766-bffe-4a74-a34a-f5517807aa73

P356

Q33400720-DD69FD5A-4B48-43D7-84CB-531AE9AB8352

P433

Q33400720-E378F089-4FFA-4A1B-BE96-9DE344D00212

P478

Q33400720-9796E503-A7AC-4089-9192-E763A75B5F67

P50

Q33400720-0A6AE028-5C07-4A57-B685-31E99040EDDB

Q33400720-44DF991E-CEA9-46B3-9425-9DF3FAF84917

Q33400720-587D3C14-2887-4C83-AF75-F6E4FE1812D1

Q33400720-5C0BB516-727C-42D1-8A61-2978156F23CC

Q33400720-5E73B249-1ADF-4B01-B2C5-4B2F9B63090B

Q33400720-ABEDF75A-23CF-44E5-9DED-5CA9934BAF10

Q33400720-EE8EFB3E-F35E-43F8-A2BA-D1E722E6F3C3

P577

Q33400720-E957160C-F8C1-4F59-A35D-E0B9279EB3E7

P5875

Q33400720-B263E9AF-898C-421B-A3B7-6A0AA9267829

P698

Q33400720-F10F6802-D888-4E4A-9C6F-367074CDDF36

P356

09031936.00022912

P1433

European Respiratory Journal

P1476

Efficacy, safety and tolerabil ...... atic review and meta-analysis.

@en

P2093

Alena Skrahina

http://www.w3.org/2001/XMLSchema#string

Elisabetta Zampogna

http://www.w3.org/2001/XMLSchema#string

Giesela F Schecter

http://www.w3.org/2001/XMLSchema#string

Holly A Anger

http://www.w3.org/2001/XMLSchema#string

Jan-William C Alffenaar

http://www.w3.org/2001/XMLSchema#string

Jean-Pierre Zellweger

http://www.w3.org/2001/XMLSchema#string

Jose A Caminero

http://www.w3.org/2001/XMLSchema#string

Lia D'Ambrosio

http://www.w3.org/2001/XMLSchema#string

Miquel Villar

http://www.w3.org/2001/XMLSchema#string

Rupak Singla

http://www.w3.org/2001/XMLSchema#string

P304

1430-1442

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1183/09031936.00022912

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

40

http://www.w3.org/2001/XMLSchema#string

P50

Giovanni Battista Migliori

Giovanni Sotgiu

Paolo Castiglia

Alimuddin Zumla

Giovanni Ferrara

Antonio Spanevello

P577

2012-04-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

223977600

http://www.w3.org/2001/XMLSchema#string

P698

22496332

http://www.w3.org/2001/XMLSchema#string